This is a multicenter, randomized, controlled, open-label, phase III study assessing the efficacy and safety of fosaprepitant, tropisetron and olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline/Cyclophosphamide-containing Chemotherapy. Eligible patients will be randomized to receive either standard antiemetic therapy (fosaprepitant, tropisetron, dexamethasone and olanzapin) or standard antiemetic therapy without dexamethasone in a 1:1 ratio.
Standard antiemetic therapy without dexamethasone for the prevention of nausea and vomiting in patients with breast cancer